RFK Jr. Overrules FDA to Open Access to Six Unproven Peptides

Health and Human Services Secretary Robert F. Kennedy Jr. has moved six unproven peptides into what the department calls an "enforcement discretion policy." In practice, that designation means federal regulators will not pursue action against the use of these substances even though they have not been approved. According to the report behind this story, the decision went ahead without the FDA's backing, which is why it is being described as an override of the agency.

Peptides, short chains of amino acids sold for everything from recovery to anti-aging, have become a fixture of wellness culture. Many are marketed through compounding pharmacies and online vendors, and the clinical evidence behind most of them is thin. Supporters in the "Make America Healthy Again" movement have pushed for looser access, arguing that the FDA has been too cautious about treatments patients want to try. Kennedy has framed his health agenda around that kind of skepticism toward federal gatekeeping, and this move fits the pattern.

Enforcement discretion is not the same as approval. A policy like this signals what regulators will prioritize, and it can lower legal risk for the businesses selling these products. It does not establish that the peptides are safe or effective, and it does not replace the human trials that would answer those questions. Buyers take on that uncertainty themselves, and doctors may find themselves fielding questions about products with little published data.

Several details remain open. The source material does not spell out the legal basis for the policy or how quality and dosing will be monitored, and it is not clear whether the FDA will issue a formal response or whether the change will draw a legal challenge. Those answers will show how far the policy reaches, and whether it stays a narrow enforcement signal or becomes a broader shift in how the government treats unapproved wellness drugs.